Cannabinoid-1 receptor inverse agonists: Current understanding of mechanism of action and unanswered questions

International Journal of Obesity

Volumn 33, Issue 9, 2009, Pages 947-955

  Fong, T M ^a,b   Heymsfield, S B ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Global Center of Scientific Affairs ^*  (United States)

^c Global Center of Scientific Affairs   (United States)

Author keywords

Body eight; Cannabinoid; CB1 receptor; Inverse agonist; Metabolism

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; DEXANABINOL; LH 21; RIMONABANT; ROSIGLITAZONE; SR 140098; TARANABANT; UNCLASSIFIED DRUG; URB 447; AMIDE; N-(3-(4-CHLOROPHENYL)-2-(3-CYANOPHENYL)-1-METHYLPROPYL)-2-METHYL-2-((5-(TRIFLUOROMETHYL)PYRIDIN-2-YL)OXY)PROPANAMIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADIPOCYTE; AUTONOMIC NERVOUS SYSTEM; BODY FAT DISTRIBUTION; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; EATING HABIT; ENERGY EXPENDITURE; FOOD INTAKE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; INVERSE AGONISM; LIPID LIVER LEVEL; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PANCREAS ISLET; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR OCCUPANCY; REVIEW; SATIETY; SKELETAL MUSCLE; TISSUE METABOLISM; WEIGHT REDUCTION; AGED; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; EATING; ENERGY METABOLISM; FEMALE; MALE; METABOLISM; OBESITY;

AGED; AMIDES; ANTI-OBESITY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENERGY METABOLISM; FEMALE; HUMANS; MALE; OBESITY; PIPERIDINES; PYRAZOLES; PYRIDINES; RECEPTOR, CANNABINOID, CB1;

EID: 70349128141     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.132     Document Type: Review

References (76)

1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
2. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 168: 299-325.
3. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Disocvery 2008; 7: 961-962.
4. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-914.
5. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-455.
6. Jesudason D, Wittert G. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol 2008; 19: 344-348.
7. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 2007; 23: 507-517.
8. Tucci SA, Halford JC, Harrold JA, Kirkham TC. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr Med Chem 2006; 13: 2669-2680.
9. Hardman JG, Limbird LE. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edn. 2001. McGraw-Hill, New York. p. 33.
10. Martin BR, Stevenson LA, Pertwee RG, Breivogel CS, Williams W, Mahadevan A et al. Agonists and silent antagonists in a series of cannabinoid sulfonamides in Symposium on the Cannabinoids 2002. International Cannabinoid Research Society:Burlington, Vermont, 2.
11. Fong TM, Guan X-M, Marsh DJ, Shen CP, Stribling DS, Rosko KM et al. Anti-obesity efficacy of a novel cannabinoid-1 receptor inverse agonist MK-0364 in rodents. J Pharmacol Exp Ther 2007; 321: 1013-1022.
12. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997; 272: 22330-22339.
13. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76: 1307-1324.
14. Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 2007; 293: R2185-R2193.
15. Sink KS, McLaughlin PJ, Wood JA, Brown C, Fan P, Vemuri VK et al. The novel Cannabinoid CB(1) receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008; 33: 946-955.
16. Rinaldi-Carmona M, Le Duigou A, Oustric D, Barth F, Bouaboula M, Carayon P et al. Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther 1998; 287: 1038-1047.
17. MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW. Evidence for inverse agonism of SR141716A at human recombinant cannabi-noid CB1 and CB2 receptors. Br J Pharmacol 1998; 124: 619-622.
18. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001; 22: 565-572.
19. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296: 678-682.
20. Auclair N, Otani S, Soubrie P, Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 2000; 83: 3287-3293.
21. Wallmichrath I, Szabo B. Analysis of the effect of cannabinoids on GABAergic neurotransmission in the substantia nigra pars reticulata. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 326-334.
22. Melis M, Pistis M, Perra S, Melis M, Pistis M, Perra S et al. Endocannabinoids mediate presynaptic inhibition of glutama-tergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 2004; 24 : 53-62.
23. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. et al. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998; 63: 113-117.
24. Arnone M, Maruani J, Chaperon F, Thiebot M, Poncelet M, Soubrie P et al. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacol 1997; 132: 104-106.
25. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metabolism 2008; 7: 68-78.
26. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-R353.
27. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/ Lep(ob) mice. Int J Obesity 2005; 29: 183-187.
28. Herling AW, Gossel M, Haschke G, Stengelin S, Kuhlmann J, Müller G et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 2007; 293: E826-E832.
29. Burns HD, Van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 2007; 104: 9800-9805.
30. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C et al. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 1995; 56: 1941-1947.
31. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612-9617.
32. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-557.
33. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151-1154.
34. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008; 57: 2977-2991.
35. Shimazu T. Liver Innervation and the Neural Control of Hepatic Function 1996. John Libbey: London, UK.
36. Romijn JA, Fliers E. Sympathetic and parasympathetic innervation of adipose tissue: metabolic implications. Curr Opin Clin Nutr Metab Care 2005; 8: 440-444.
37. Love JA, Yi E, Smith TG. Autonomic pathways regulating pancreatic exocrine secretion. Auton Neurosci 2007; 133: 19-34.
38. Uyama N, Geerts A, Reynaert H. Neural connections between the hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol 2004; 280: 808-820.
39. Gilon P, Henquin JC. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr Rev 2001; 22: 565-604.
40. Teff KL. Visceral nerves: vagal and sympathetic innervation. JPEN J Parenter Enteral Nutr 2008; 32: 569-571.
41. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
42. Kunos G, Osei-Hyiaman D, Batkai S, Sharkey KA, Makriyannis A. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 2009; 30: 1-7.
43. Perio A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, Soubrié P et al. Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 1996; 7: 65-71.
44. Pavon FJ, Bilbao A, Hernandez-Folgado L, Cippitelli A, Jagerovic N, Abellán G et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-di-chlorophenyl)-3- hexyl-1H-1,2,4-triazole-LH 21. Neuropharmacol-ogy 2006; 51: 358-366.
45. Chen RZ, Frassetto A, Lao JZ, Huang RR, Xiao JC, Clements MJ et al. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur J Pharmacol 2008; 584: 338-342.
46. LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett 2009; 19: 639-643.
47. Maness LM, Banks WA, Zadina JE, Kastin AJ. Periventricular penetration and disappearance of ICV Tyr-MIF-1, DAMGO, tyrosine, and albumin. Peptides 1996; 17: 247-250.
48. Dratman MB, Crutchfield FL, Schoenhoff MB. Transport of iodothyronines from bloodstream to brain: contributions by blood:brain and choroid plexus:cerebrospinal fluid barriers. Brain Res 1991; 554: 229-236.
49. Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H, Williams T et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 2005; 123: 493-505.
50. Verty AN, Allen AM, Oldfield BJ. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring) 2009; 17: 254-261.
51. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003; 302: 84-88.
52. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160-3169.
53. Cota D, Marsicano G, Tschop M, Grübler Y, Flachskamm C, Schubert M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003; 112: 423-431.
54. Shen CP, Xiao JC, Armstrong H, Hagmann W, Fong TM. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist. Eur J Pharmacol 2006; 531: 41-46.
55. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
56. Turpault S, Kanamaluru V, Lockwood GF, Bonnet D, Newton J. Rimonabant pharmacokinetics in healthy and obese subjects. Clin Pharmacol Ther 2006; 7950.
57. Lofgren P, Sjolin E, Wahlen K, Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 2007; 92: 1555-1559.
58. Hamilton B, Allgaeuer S, Getta P, Halder A, Lorenz A, Rist S et al. Do adipose tissue cannabinoid CB1 receptor modulate adiponec-tin expression or lipolysis? Obesity Res 2005; 13, (2005 NAASO Program Abstract Supplement)-A162.
59. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007; 92: 4810-4819.
60. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91 : 3171-3180.
61. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Javier Díaz-Molina F, Ripoll C, Rodríguez de Fonseca F et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006; 39: 155-162.
62. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca(2+) oscillation in islet beta-cells via CB1 receptors. Regul Pept 2008; 145: 49-53.
63. Getty-Kaushik L, Richard AM, Deeney JT, Shirihai O, Corkey BE. Rimonabant decreases insulin hypersecretion in islets from Zucker rats. In. 2007 ADA Annual Scientific Sessions 2007. American Diabetes Association: IL, Chicago. p 1735.
64. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 2007; 267: 63-69.
65. Irwin N, Hunter K, Flatt PR. Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice. Peptides 2008; 29: 1036-1041.
66. Tonstad S. Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors? Nat Clin Pract Cardiovasc Med 2006; 3: 364-365.
67. Blundell JE, Goodson S, Halford JC. Regulation of appetite: role of leptin in signalling systems for drive and satiety. Int J Obes Relat Metab Disord 2001; 25: S29-S34.
68. Halford JC, Cooper GD, Dovey TM. The pharmacology of human appetite expression. Curr Drug Targets 2004; 5: 221-240.
69. Blundell JE, Jebb SA, Stiubbs RJ, Wilding JR, Lawton S, Halford JCG et al. Effcet of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. Obesity Rev 2006; 7: 104, Wiley-Blackwell.
70. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004; 24 : 2708-2715.
71. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589.
72. Perio A, Barnouin MC, Poncelet M, Soubrie P. Activity of SR141716 on post-reinforcement pauses in operant responding for sucrose reward in rats. Behav Pharmacol 2001; 12: 641-645.
73. Freedland CS, Poston JS, Porrino LJ. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 2000; 67: 265-270.
74. Rowland NE, Mukherjee M, Robertson K. Effects of the cannabi-noid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl) 2001; 159: 111-116.
75. Verty AN, McGregor IS, Mallet PE. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 2004; 354: 217-220.
76. Koch JE. Delta(9)-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav 2001; 68: 539-543.